Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023764 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Lymphoproliferative Disorders
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT00023764: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00023764 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023764, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have low-grade lymphoproliferative disorders. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2001-06 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023764
The ClinicalTrials.gov registry entry for NCT00023764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00023764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023764 about?
NCT00023764 is a clinical study titled "Bortezomib in Treating Patients With Lymphoproliferative Disorders". Phase II trial to study the effectiveness of bortezomib in treating patients who have low-grade lymphoproliferative disorders. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
What is the current status of trial NCT00023764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2001-06. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00023764?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00023764?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.